Brief: Abbisko Cayman Says Absk021 Phase Iii Tgct Clinical Trial Approved By EMA
11/09/2023 02:41
Sept 11 (Reuters) - Abbisko Cayman Ltd 2256.HK :
* ABSK021 PHASE III TGCT CLINICAL TRIAL APPROVED BY EMA
Further company coverage: 2256.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Cayman
See all newsHK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)
Brief: Abbisko Therapeutics Deepens R+D- Collaboration With Lilly
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly